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Prostate cancer is the most common solid tumor in men, and it
shares with all cancers the hallmark of elevated, nonhomeostatic
cell proliferation. Here we have tested the hypothesis that the
SONIC HEDGEHOG (SHH)–GLI signaling pathway is implicated in
prostate cancer. We report expression of SHH–GLI pathway com-
ponents in adult human prostate cancer, often with enhanced
levels in tumors versus normal prostatic epithelia. Blocking the
pathway with cyclopamine or anti-SHH antibodies inhibits the
proliferation of GLI1PSA primary prostate tumor cultures. In-
versely, SHH can potentiate tumor cell proliferation, suggesting
that autocrine signaling may often sustain tumor growth. In
addition, pathway blockade in three metastatic prostate cancer cell
lines with cyclopamine or through GLI1 RNA interference leads to
inhibition of cell proliferation, suggesting cell-autonomous path-
way activation at different levels and showing an essential role for
GLI1 in human cells. Our data demonstrate the dependence of
prostate cancer on SHH–GLI function and suggest a novel thera-
peutic approach.
SONIC HEDGEHOG (SHH) signaling has been implicated indifferent aspects of animal development, acting through several
components, including the transmembrane proteins PATCHED1
(PTCH1) and SMOOTHENED (SMOH), to activate the GLI
zinc-finger transcription factors (1, 2). In addition, we and others
have shown that SHH signaling is implicated in a number of tumors
(reviewed in refs. 2 and 3), such as basal cell carcinomas (4–6),
medulloblastomas (7, 8), gliomas (7), sarcomas (9, 10), tumors of
the digestive tract (11), small cell lung cancers (12,) and pancreatic
carcinomas (13). To date there is no direct evidence linking SHH
signaling to prostate cancer, the most common solid cancer in men
(14), although we have found that sporadic prostate tumors express
GLI1 (7), a reliable marker of SHH signaling (15, 16). This
observation allowed us to propose the hypothesis that the SHH–
GLI pathway participates in prostate cancer (7). Consistently, Shh
signaling has been found to be essential for prostate patterning and
development (17–22), and genetic mapping data has revealed that
at least two key components of the SHH–GLI pathway [SMOH and
SUPPRESSOR OF FUSED (SUFUH)] are located in chromosomal
regions implicated in familial human prostate cancer (23, 24). Here
we have tested the involvement of SHH–GLI signaling in prostate
cancer.
Methods
Cell Lines and Primary Cultures. The PC3, LNCaP, and DU145 cell
lines (25–27) were purchased from American Type Culture Col-
lection and grown as specified. All primary prostate tumors were
obtained following approved protocols. Tumors in PBS were
chopped with a razor blade and incubated with Papain for 1 h at
37°C, they were then dissociated by passing them through a
fire-polished pipette and washed several times in serum containing
media. All dissociated primary tumors were plated in polyornithin-
and laminin-treated p16 plates in DMEM-F12 with 10% FBS at
30,000 cells per p16 well. Primary cultures were used 2–4 days
after plating, when the cells reached 60–70% confluence.
In Situ Hybridization and Immunocytochemistry. Immunocytochem-
istry was performed with anti-BrdUrd (Beckton Dickinson), anti-
SHH (Santa Cruz Biotechnology), and anti-Ki-67 (DAKO), using
FITC- or horseradish peroxidase (HRP)-conjugated secondary
antibodies (Boehringer Mannheim) as described (7). For tissue
arrays, slides were baked and deparaffinized before blocking of
endogenous peroxides. They were then developed with HRP-
conjugated secondary antibodies and diaminobenzidine (DAB). In
situ hybridizations on frozen sections with digoxygenin-labeled
antisense RNA probes for GLI1, PTCH1, and SHH and a sense
control GLI1 were as described (7).
Prostate Tissue Microarrays and Microdissection. After institutional
review board approval, tissue microarrays (28) were prepared from
archived paraffin blocks from 288 radical prostatectomy cases from
the Medical College of Wisconsin. For each case, 0.6-mm cores of
tumor were isolated and placed in the array blocks, and 5-m slides
were prepared for immunohistochemistry. Slides were reviewed by
a trained urologic pathologist (M.W.D.) and scored for the pres-
ence of benign prostate glands, high-grade prostatic intraepithelial
neoplasia, or invasive tumor. The presence of tumor or high-grade
prostatic intraepithelial neoplasia was confirmed by immunohisto-
chemical staining for high molecular mass cytokeratin (CK903 Ab,
DAKO). Individual cores were examined as duplicates, and stain-
ing was correlated to a set of anonymous deidentified pathologic
and outcomes data with 2 and Fisher’s exact or two-tailed
ANOVA analyses.
Normal and tumor tissue from the same patients for real-time
PCR analyses were microdissected from sections with a laser
capture microscope after pathological assessment.
SHH, Anti-SHH Antibody, Cyclopamine, and Tomatidine Treatments.
Commercial N-SHH (R & D Systems) was used at 100 nM because
we have found that this commercial protein is20 times less active
than the octyl-modified SHH-N we had previously used from Curis
in the C3H10T12 induction assay (data not shown). 5E1 anti-SHH
blocking antibody (29) was purchased from the Hybridoma Bank at
the University of Iowa and was used at 8 gml. Cyclopamine
(Toronto Research Chemicals) and Tomatidine (Sigma) were used
at 10 M unless otherwise noted; for cells in culture, they were
dissolved in ethanol, and ethanol alone was used as control. Treated
cells were in 2.5% serum for 48 h instead of the usual 10% routinely
used for standard growth.
Proliferation Assays. BrdUrd (Sigma) was given at 4 gml before
fixation. The time of the BrdUrd pulse depended on the growth rate
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of the cells tested. Cell lines were given a 2-h pulse, whereas primary
tumor cultures, which grow less rapidly, were given 16-h pulses.
Proliferation in tissue arrays was measured by the level of Ki-67
antigen expression.
PCRs. For RT-PCRs, the following primers were used (all 5 to
3). GLI1s, GGGATGATCCCACATCCTCAGTC, and GLI1a,
CTGGAGCAGCCCCCCCAGT at 60°C; PSAs, CTTGTAGC-
CTCTCGTGGCAG, and PSAa, GACCTTCATAGCATCCGT-
GAG at 56°C. Primers for PTCH1 and GAPDH were as de-
scribed (7, 30).
For real-time PCR, total RNA was DNase treated (Invitrogen)
and reverse transcribed with TaqMan (Applied Biosystems) using
oligo(dT) primers as described by the manufacturer. Reactions
were run by using SYBR Green (Applied Biosystems) on an ABI
Prism 7700 machine. Each sample was run minimally at three
concentrations in triplicate. All primer sets amplified 75- to 300-bp
fragments. Sequences are available upon request. The raw data are
available upon request from S.D.
RNA Interference. Double-stranded small interference RNAs (siR-
NAs, 21 nt long) were purchased from Dahrmacon, purified, and
desalted. The sequences for the GLI1 siRNAs used was: AACUC-
CACAGGCAUACAGGAU; control siRNA was: AACGUA-
CGCGGAAUACAACGA. This siRNA was also used FITC-
tagged. siRNA transfections (0.2 M) were with Oligofectamine
(Invitrogen) as described by the manufacturer. Cells were treated
for 60 h before fixation.
Results
To begin to analyze the role of SHH–GLI signaling in prostate
cancer, we first tested for the expression of SHH–GLI pathway
components in prostate cancer resections and normal tissue
from the same patients. In situ hybridization showed that GLI1,
PTCH1, and SHH are normally coexpressed in epithelial cells
and not in the surrounding stroma (Fig. 1 A, C, E, G, I, L, and
O). Prostate tumors were uniformly SHHGLI1PTCH1
(Fig. 1 B, D, F, H, J, K, M, N, P, and Q), although variable levels
of expression were detected visually in the tumors. Coexpression
of these markers in tumor cells is consistent with their derivation
from the normal prostatic epithelium.
More sensitive real-time PCR analyses of six of the same micro-
dissected matched pairs showed up-regulation of the expression of
SHH, PTCH1, GLI1, GLI2, and GLI3 (between 1.5- and 300-
fold) in many tumor cases compared to normal tissue after nor-
malization to the ubiquitous similar expression of -actin (Table 1).
Levels of expression within tumors were variable. Such differences
could be related to the known heterogeneity of prostate cancer,
because this is a general diagnosis that encompasses a broad range
of histological phenotypes (31–33). Whereas varying levels have
also been observed in other tumors (reviewed in refs. 2 and 3), the
meaning of such differences is not known, although they have been
proposed to correlate in a direct or inverse manner with tumor type
or grade (34–36). What is important is that the loyal markers of an
active SHH–GLI pathway, GLI1 and PTCH1 (refs. 15, 16, and 37),
are consistently transcribed in the examined tumor cells, showing
the presence of an active pathway.
To extend these findings, we performed immunohistochemistry
for SHH, as a secreted and potentially useful systemic marker for
prostate cancer, on tissue microarrays representing 239 prostate
carcinomas, 15 precancerous lesion high-grade prostatic intraepi-
thelial neoplasia (HGPIN), and 135 benign prostate tissues from
297 patients. SHH expression was increased in tumors and was
present as a secreted protein in the glandular lumens made by
tumor cells (Fig. 1 R–T), likely reflecting the origin of tumors from
the SHH prostatic epithelia. Higher SHH levels, determined
visually, were found in 33% of tumors compared to 1% of cases
of normal adjacent tissue, indicating a significant correlation be-
tween high SHH levels and tumor presence. High SHH levels were
also correlated with higher Ki-67 cell proliferation (Table 2). The
level of SHH expression was not correlated with Gleason score or
other clinical parameters (Table 2). This finding may indicate that
inappropriately maintained or elevated SHH expression is an early
and general event in prostate cancer, reflecting the origin of tumors
from the SHH prostatic epithelia.
The difficulty of growing human prostate cancer cells in vitro
translates into a dearth of available cancer cells to test. Here we
have chosen the three most widely used prostate cancer cell lines,
LNCaP, an androgen sensitive cell line derived from a prostate
cancer lymph node metastasis; and PC3 and DU145, androgen
insensitive cell lines derived from prostate cancer bone metastases,
to assay for the expression of SHH–GLI pathway components. All
of the cells expressed GLI1 and PTCH1 (Fig. 2A), consistent with
our expression studies and indicating that they harbor an active
pathway. Of these cell lines, only DU145 and PC3 cells expressed
GLI2, and only LNCaP and PC3 cells expressed GLI3 and SHH at
detectable levels (Fig. 2A). GLI1 is thus the only GLI gene
consistently expressed at detectable levels in all of these cells, and
thus, we have focused on GLI1.
To interfere with SHH–GLI signaling, we first used cyclopamine,
a selective inhibitor of SMOH (38). Effects of cyclopamine treat-
ment after 48 h were tested by BrdUrd incorporation as a sensitive
measure of cell proliferation. Such treatment led to a large (80%)
decrease in BrdUrd incorporation in LNCaP cells, and a significant
decrease (30%) in PC3 cells but had no effect in DU145 cells (Fig.
2B). Treatment with tomatidine (38) served as control and had little
or no effect on BrdUrd incorporation (Fig. 2B). The lack of effects
of cyclopamine on DU145 cells shows that this drug is not non-
specific. Because we used short-term assays to focus on early, direct
effects on cell proliferation, the changes in total cell number were
consequently relatively conservative. For instance, cyclopamine
reduced total 4,6-diamidino-2-phenylindole-positive LNCaP cell
number by 22.1 1.1% (P 0.0001) after 48 h. No cytotoxic effects
or significant cell death were observed during these experiments.
Cyclopamine treatment also led to a decrease in GLI1 expression,
consistent with the expected down-regulation of the SHH–GLI
pathway (Fig. 2C).
Analyses of primary prostate tumors is complicated by the
difficulty of growing primary human prostate cancer cultures (39).
Nevertheless, we were able to dissociate and plate six of eight
primary prostate tumors, although stable cultures were not ob-
tained. Primary cells that remained attached after 2 days had a
uniform cuboidal morphology, formed small clusters and expressed
prostate-specific antigen (PSA), as well as SHH, PTCH1, and GLI1
(Fig. 2D), proving their prostatic epithelial origin. Cyclopamine
treatment led to a major (70%) decrease in BrdUrd incorporation
in all primary cultures as compared with carrier-treated samples
(Fig. 2 E–G), mimicking the results obtained in LNCaP cells. Here
again, the insensitivity of DU145 to cyclopamine provides a control
for the action of the drug. Indeed, although we have not tested the
response of normal human prostate cells to cyclopamine, we expect
that it would also inhibit the proliferation of normal SHH
PTCH1GLI1 prostate epithelial cells (Fig. 1). As with the cell
lines, the total number of 4,6-diamidino-2-phenylindole-positive
primary tumor cells was similarly reduced by cyclopamine treat-
ment [e.g., 26.7  1.1% decrease in primary tumor 6 (PT6), P 
0.001] after 48 h. Although stromal cells are likely to be present in
our primary cultures, their numbers appear to be small because
90% of the cells examined microscopically had a similar cuboidal
morphology. Moreover, the high inhibition levels by cyclopamine
would be inconsistent with effects only in contaminating stromal
cells, which do not appreciably express PTCH1 or GLI1 (Fig. 1).
We then tested for the ability of exogenous SHH to stimulate
prostate cancer cell proliferation and for the possible existence of
autocrine signaling. Addition of recombinant SHH protein led to an
increase in BrdUrd incorporation in two of four primary cultures
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after 48 h (Fig. 2 F, H, and J). In contrast, addition of the standard
blocking antibody against SHH (5E1; ref. 29) resulted in a inhibition
of BrdUrd incorporation by 15–40% for three of four tumors (Fig.
2 F, I, and K), suggesting that several tumors display autocrine
signaling. Interestingly, the only primary culture that was insensitive
to Shh Ab blockade, PT7, being sensitive to cyclopamine [which
targets SMOH (38), Fig. 2E], was also the more sensitive to the
addition of exogenous Shh. This might indicate that although the
pathway is activated downstream of the site of ligand action in PT7,
possibly affecting PTCH1 or SMOH, exogenous Shh can still
increase the levels of signaling. Taken together, the functional
heterogeneity that we detect parallels that found for GLI and SHH
expression described above and may reflect independent activating
events as well as the well known heterogeneity of prostate cancers.
Treatment of LNCaP, PC3 or DU145 cells with either blocking
antibody or recombinant Shh protein did not result in significant
Fig. 1. Expression of SHH–GLI pathway components in normal prostate tissue and prostate tumors. Sections of normal prostate tissue (A, C, E, G, I, L, and O)
and prostate tumors (B, D, F, H, J, K, M, N, P, and Q) show hematoxylin and eosin (H&E) staining (A and B) or the expression of SHH (C, D, and I–K), PTCH1 (E,
F, and L–N), and GLI1 (G, H, and O–Q). (G Inset) Sense GLI1 probe control showing no background. Prostate tumors have many small epithelial glandular structures.
Black arrows point to expressing cells. White arrows point to nonexpressing cells. (R–T) Sections from the tissue microarrays of normal prostate tissue (R) and
prostate tumors (S and T) showing expression of SHH protein with an anti-SHH antibody (SHH Ab) (R–T) and a no-primary antibody control (T Inset). All sections
were counterstained with hematoxylin to visualize nuclei and tissue structure. Arrow in T points to localization of SHH protein in the cytoplasm of epithelial cells.
e, epithelium; l, lumen; s, stroma; t, tumor. (Scale bar in T is 150 m in A–H, R, and S, 20 m in J, M, P, and T, and 10 m in I–L, N, O, and Q.)
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changes in BrdUrd incorporation (data not shown). LNCaP and
PC3 cells could thus display an activated pathway at the membrane
level (being sensitive to cyclopamine inhibition) that has lost
responsiveness to ligand. Cyclopamine-insensitive DU145 cells may
have an activated pathway downstream of SMOH (or at the level
of SMOH affecting its inhibition by cyclopamine), having lost also
the ability to respond to SHH. It remains possible that the different
behavior of primary cultures versus established cell lines also
reflects unrelated transformation or immortalization events.
The GLI zinc-finger transcription factors have been suggested to
be essential for the mediation of HH signals (reviewed in refs. 1, 2,
and 40). However, Gli1 is apparently redundant in mouse devel-
opment and tumorigenesis (41, 42), and there is to date no data on
the requirement for GLI1 in human cells. Here, we tested the
function of GLI1, the only GLI gene consistently expressed in all
primary tumors and cell lines, by RNA interference to knockdown
its function with a specific 21-nt-long small RNA. (This siRNA
inhibits the effect of SHH on multipotent C3H10T12 cells; P.S.
and A.R.A., unpublished data). Lipofection of primary cultures
resulted in a negligible number of transfected cells, making it
impractical to use siRNAs in such cultures. In contrast, lipofection
of FITC–siRNA proved efficient (50–80%) in the LNCaP, PC3,
and DU145 cell lines (Fig. 3 A–C). It is important to note that,
because transfection efficiencies are100%, the results of cell pool
assays necessarily underestimate the effects of RNA interference.
Transfection of a control siRNA at the same concentration served
as control in all tests.
The specificity of the GLI1 siRNA was further tested in LNCaP
cells. Reduction of GLI1 mRNA levels by the GLI1 siRNA was
detected as early as 3 h after transfection and at 8 and 24 h, but not
at 48 h (Fig. 3 D and F and data not shown), suggesting up-
regulation of GLI1 after its inhibition, possibly because of the action
of a rapid positive feedback loop (7, 43). GLI1 siRNA also robustly
repressed PTCH1, a result most clearly seen at 48 h, but not the
housekeeping gene GAPDH (Fig. 3D and data not shown). Because
PTCH1 is a SHH target (37), and in particular of GLI1 (44), this
result indicates that interference with GLI1 function by RNAi is
selective and effective in prostate cancer cells. GLI1 siRNA also
decreased GLI1 mRNA levels in DU145 and PC3 cells after 8 h
(Fig. 3F).
Inhibition of GLI1 by RNA interference led to a variable
reduction in BrdUrd incorporation in all three cell lines, with
strongest effects (60%) in LNCaP cells (Fig. 3E). These cells are
thus very sensitive to inhibition by cyclopamine and GLI1 inter-
ference, suggesting the presence of a fully active canonical pathway
activated at the level of SMOH or upstream, but downstream of
SHH, because treatment with the blocking anti-SHH Ab had no
effect. DU145 cells are not sensitive to cyclopamine, but are
sensitive to GLI1 interference, suggesting activation downstream of
SMOH and upstream or at the level of GLI1 function. In contrast,
PC3 cells are sensitive to cyclopamine and less so to GLI1 inter-
ference, perhaps suggesting compensation by the other GLI pro-
teins because PC3 cells express GLI2 [and this GLI gene mediates
SHH signals (45) and can behave like Gli1 in mice (46)] or the
presence of alternate pathways for tumor cell proliferation. We
note, however, that lipofection efficiencies in PC3 cells (Fig. 3C) are
the lowest (50%) of the three cells tested, indicating that the real
effects of GLI1 interference may be higher. Taken together, our
results show the requirement of GLI1 in human prostate tumor
cells.
Discussion
Here we demonstrate the dependence of prostate cancer cell
proliferation on SHH–GLI pathway activity. The data suggest
activation of the pathway at different levels in primary prostate
tumors and cell lines derived from metastatic lesions. These find-
ings, together with the involvement of this pathway in normal
prostate development and growth (17–22), indicate that the normal
patterning role of SHH–GLI signaling is deregulated in cancer. This
Table 1. SHH, GLI1, GLI2, GLI3, and PTCH1 expression in human prostate cancer
Patient
SHH PTCH1 GLI1 GLI2 GLI3
Fold
increase Range
Fold
increase Range
Fold
increase Range
Fold
increase Range
Fold
increase Range
829 0 0–0.01 1.5 1.1–2.1 26.1 20.8–32.7 0.02 0.02–0.02 72 53–99
887 0.2 0.05–0.9 8.5 7.6–9.5 0.09 0.07–0.13 0.43 0.37–0.51 1.1 0.8–1.6
921 2.9 1.3–6.3 50 30–84 2 1.1–3.4 3.8 2.4–6.1 12.5 7.7–20.4
945 9.8 6.2–15.7 7.8 5.7–10.7 22.7 21.6–23.9 0.7 0.5–1.0 2.2 2.1–2.4
1854 4.7 1.8–11.7 213 164–278 5.1 3.8–6.9 19.5 10.9–35.1 5.7 4.4–7.5
1866 4.6 4.1–5.2 3.4 3.1–3.7 299 260–342 0.03 0.02–0.03 0.18 0.15–0.2
Fold increase in gene expression in tumors versus matched normal tissue determined by real-time RT-PCR analyses as calculated by the CT method. Range
indicates  1 SD. Gene expression levels were normalized to -actin. Increases of 2-fold or more are shown in bold.
Table 2. Correlation of elevated SHH expression with
tumorigenesis and clinical features of prostate cancer
SHH
2 or Fisher’s
exact test
Expression
low
Expression
high
Histology Tumor 141 70
Normal 126 1 P  0.00005
HGPIN 13 1
Normal 126 1 P  0.0563
Clinical stage cT2 16 6
cT34 2 1 NS
Tumor grade Gleason 6 30 1
Gleason 7,8,9 57 7 NS
Pathologic
stage
pT1–pT2
pT3
50
37
4
4 NS
Nodal status pN0 27 12
pN1 1 0 NS
Outcomes PSA Recurrence 8 1
No PSA
recurrence
22 12 NS
Vital status Alive 42 18
Dead 4 3 NS
Ki-67 Sample no. 275 69
expression Mean % Ki-67
nuclei
5.1 7.6 P  0.0141*
Significance was only found between SHH expression and tumorigenesis
and SHH expression and higher proliferative levels as measured by Ki-67
staining. Tumor grade is presented as Gleason score. Pathologic staging uses
the American Joint Comission on Cancer 2002 tumor staging criteria. HGPIN,
high-grade prostatic intraepithelial neoplasia.
*Two-tailed ANOVA.
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idea is consistent with the proposed events in other tissues, includ-
ing brain, lung, stomach, muscle, pancreas, and skin, in which the
SHH–GLI pathway regulates patterned growth and when deregu-
lated can give rise to SHH–GLI-dependent tumors (reviewed in
refs. 2 and 3). Thus, there is a surprising and unexpected parallel in
the requirement of SHH–GLI signaling of prostate tumors with
those in organs of very different origin, function, and location.
The deduction that prostate tumors display activation at different
levels is consistent with findings in brain (ref. 7 and P.S. and A.R.A.,
unpublished data) and pancreatic (14) tumors, even though the
entire set of activating events or mutations have not been described
in any case. Indeed, our data suggest that the regulation of the
SHH–GLI pathway in the normal prostatic epithelium is altered
away from homeostasis in the tumors by epigenetic events or
mutations in components such as PTCH1, SMOH, or SUFUH,
similar to those already found in other tumors (e.g., refs. 47–53).
However, the finding that the pathway is active as assessed by the
expression of GLI1 and PTCH1 [as in the case of basal cell
carcinomas (6), medulloblastomas (7), and gliomas (7)] allows us to
bypass the identification of the likely myriad of activating events to
discern that tumor cells harbor an active pathway. Indeed, the
finding that SHH expression levels are not correlated with Gleason
score, but that all prostate tumor samples tested require continued
pathway activity for proliferation, allows us to propose that this
pathway is a critical and essential component of prostate cancer.
Specifically, we show the requirement for SHH, SMOH, andor
GLI1 for the proliferation of prostate cancer cells. The fact that all
primary tumors tested are sensitive to cyclopamine indicates that
SMOH, or upstream elements from it, are common targets leading
to the activation of downstream mediators. Several primary cultures
are also sensitive to inhibition by blocking anti-SHH Ab, suggesting
that, like in stomach tumors (11), autocrine signaling is a frequent
cause of pathway activation in prostate cancer. The consistent
expression of GLI1 in tumor cell lines and in primary tumors
together with the effects of RNA interference indicate that this GLI
gene plays a central and general role in prostate tumor cell
proliferation, and demonstrate its requirement in human tumori-
genesis. In contrast, GLI2 and GLI3 do not appear to be consis-
tently expressed in prostate cancer cells. When expressed, they
could have complementary or compensatory roles in some cases,
although their roles remains to be determined.
Prostate cancer is thought to develop from a lesion in the
epithelial layer to become an invasive tumor that spreads within the
prostate and subsequently acquires the potential to metastasize to
distant sites, most often the lymph nodes and bone (54). Inhibition
of testosterone-dependent tumor growth is the common treatment
for advanced disease, but subsequent hormone-independent cell
Fig. 2. Response of prostate tumor cell lines to alterations in the SHH–GLI
pathway. (A) PCR analyses for the expression of SHH–GLI pathway compo-
nents in three cell lines as indicated. In this and all other PCR assays, the
expression of the ubiquitous gene GAPDH is measured as quantitative control.
(B) Inhibition of prostate cell line proliferation as measured by BrdUrd incor-
poration in the three prostate cell lines used with cyclopamine. Tomatidine is
used as control. (C and D) PCR analyses of the suppression of GLI1 expression
in LNCaP cells by cyclopamine treatment at 36 h (C) or of the expression of
prostate specific antigen (PSA), GLI1, SHH, and PTCH1 expression in whole
prostate tumor tissue (T), primary culture (C), the glioblastoma cell line U87
(U), and LNCaP (L) cells (D). PSA is expressed in prostate but not in brain cells.
All samples express GLI1 and SHH. The whole tissue and primary culture
correspond to PT6. (E) Histogram of the inhibition of BrdUrd incorporation in
primary cultures of prostate tumor (PT3-PT8) by cyclopamine treatment. (F–I)
Immunocytochemistry for BrdUrd incorporation with secondary FITC-
antibodies showing BrdUrd nuclei (green) in a field of primary prostate cells
(PT6) in control cells (treated with ethanol as the carrier for cyclopamine, F),
cyclopamine (G), SHH protein (H), or anti-SHH antibody (SHH Ab, I). All nuclei
are stained with 4,6-diamidino-2-phenylindole (blue). (J and K) Histograms of
the increase in (J) or inhibition of (K) BrdUrd incorporation of primary prostate
tumors after treatment with SHH (J) or anti-SHH antibody (SHH Ab, K) for
48 h. Histogram error bars represent SEM in all panels.
Fig. 3. Response of prostate cell lines to GLI1 RNA interference. (A–C)
Immunocytochemisty of the three prostate cell lines indicated showing the
efficiency of lipofection of an FITC-tagged control siRNA (green). Note the
lower efficiency in PC3 cells. (D) Effect of GLI1 siRNA on gene expression. RNA
interference reduces GLI1 and PTCH1 mRNA levels as seen at 24 and 48 h,
respectively (E) Histogram of the inhibition of BrdUrd incorporation in pros-
tate tumor cell lines by GLI1 siRNA. (F) Specificity of the effects of GLI1 siRNA
on GLI1 mRNA levels in the three prostate cell lines, compared with those of
a control unrelated siRNA, 8 h after transfection. The levels of GAPDH are
shown below as controls.
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proliferation and metastasis often leads to patient death (55). Our
data on the behavior of the three prostate cancer cell lines derived
from metastatic lesions suggest that such tumors could harbor
additional changes that may make them ligand-independent, albeit
still being SHH–GLI pathway dependent, and explain their differ-
ential behavior in comparison with the primary cultures. Perhaps
the gain of intracellular, cell-autonomous activation of the SHH–
GLI pathway represents an advantage for metastatic cells, allowing
efficient proliferation far from the prostatic epithelium, where SHH
appears to be continually and abundantly produced.
The high inhibition of proliferation by SHH–GLI pathway block-
ade of the presumed androgen-sensitive primary tumors used in this
study, which derive from patients that did not receive hormone
treatments, and of the androgen-sensitive LNCaP cell line might be
related to the proposed requirement of Shh signaling for normal
androgen function, because defects derived from loss of Shh
signaling in mice can be rescued by exogenous androgens (22).
Prostate cancer could therefore initiate through inappropriate
maintenance or enhanced activity of SHH–GLI signaling, and more
aggressive (androgen insensitive) states may require additional
alterations. Nevertheless, the inhibition of the androgen-insensitive
DU145 cell line by RNA interference suggests that even highly
aggressive tumors may be sensitive, albeit to different degrees, to
GLI1 inhibition.
Prostate stem cells may play a critical role in the epithelial
development and homeostasis (56, 57). Because cancer may be a
disease of stem cell lineages (discussed in refs. 2, 3, 40, and 58) and
SHH–GLI signaling controls the behavior of precursors and of cells
with stem cell properties in the mammalian brain (e.g., refs. 30, 59,
and 60 and V. Palma, D. Lim, N. Dahmane, N., P.S., Y. Gitton, A.
Alvarez-Buylla, A., and A.R.A., unpublished data) and in other
tissues and species (61, 62), prostate cancer might derive from
inappropriate expansion of prostatic epithelial stem cell lineages
caused by abnormal SHH–GLI function.
Finally, our data suggest that SHH and GLI1 may not only be
useful markers for prostate cancer but also good targets for
anticancer therapies, with emphasis on GLI function as the last and
essential step of the pathway, the inhibition of which will likely block
signaling by upstream events at any level. SHH–GLI pathway
blocking agents should thus provide attractive therapeutic strategies
to combat prostate cancer of any grade.
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